重新评估PAGE-B相关评分预测慢性乙型肝炎患者肝细胞癌发生的准确性
研究基于香港全港数据库32,150例接受恩替卡韦或替诺福韦治疗至少6个月的慢性乙型肝炎患者,评估PAGE-B和mPAGE-B评分预测5年肝细胞癌(HCC)发生的性能。结果显示mPAGE-B的AUROC为0.80,PAGE-B为0.77;任一分值判定为低危的患者5年HCC累积发生率为0.6%,阴性预测值达99.5%,可考虑豁免HCC监测。
要点
- mPAGE-B预测5年HCC的AUROC为0.80,优于PAGE-B的0.77。
- 任一分值判定低危者5年HCC累积发生率仅0.6%,阴性预测值99.5%。
- PAGE-B与mPAGE-B在基线及治疗2年时的预测性能相似。
核心结论
- PAGE-B和mPAGE-B评分可用于识别抗病毒治疗中HCC低风险患者,这些患者可考虑豁免HCC监测。
研究设计与样本
- 回顾性队列研究,纳入2005年1月至2018年6月香港全港数据库中接受恩替卡韦或替诺福韦至少6个月的连续成人慢性乙型肝炎患者32,150例。
主要发现
- 中位随访3.9年(IQR 1.8-5.0)期间,1,532例(4.8%)发生HCC。
- 预测5年HCC的AUROC(95%CI)PAGE-B为0.77(0.76-0.78),mPAGE-B为0.80(0.79-0.81),p<0.001。
- 9,417例(29.3%)被任一分值归为低危,其5年HCC累积发生率为0.6%(0.4%-0.8%)。
- 该分类排除5年无HCC发生的阴性预测值为99.5%(99.4%-99.7%)。
- PAGE-B与mPAGE-B在基线及治疗2年时的AUROC相似。
关键数值与推荐
- PAGE-B预测5年HCC的AUROC为0.77(95%CI 0.76-0.78)。
- mPAGE-B预测5年HCC的AUROC为0.80(95%CI 0.79-0.81)。
- 任一分值低危者5年HCC累积发生率0.6%(95%CI 0.4%-0.8%),阴性预测值99.5%(95%CI 99.4%-99.7%)。
临床怎么用
- 对接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者,可用PAGE-B或mPAGE-B评分识别HCC低风险者。
- 任一分值判定为低危的患者因HCC风险极低,可考虑豁免HCC监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: PAGE-B and modified PAGE-B (mPAGE-B) scores were developed to predict the risk of hepatocellular carcinoma (HCC) in patients on nucleos(t)ide analogue therapy. However, how and when to use these risk scores in clinical practice is uncertain. METHODS: Consecutive adult patients with chronic hepatitis B who had received entecavir or tenofovir for at least 6 months between January 2005 and June 2018 were identified from a territory-wide database in Hong Kong. The performance of PAGE-B and mPAGE-B scores for HCC prediction at 5 years was assessed by area under the time-dependent receiver operating characteristic curve (AUROC), and different cut-off values of these 2 scores were evaluated by survival analysis. RESULTS: Of 32,150 identified patients with chronic hepatitis B, 20,868 (64.9%) were male. Their mean age was 53.0 ± 13.2 years. At a median (IQR) follow-up of 3.9 (1.8-5.0) years, 1,532 (4.8%) patients developed HCC. The AUROCs (95% CI) for the prediction of HCC at 5 years were 0.77 (0.76-0.78) and 0.80 (0.79-0.81), with PAGE-B and mPAGE-B scores, respectively (p <0.001). A total of 9,417 (29.3%) patients were classified as having a low HCC risk by either PAGE-B or mPAGE-B scores; their 5-year cumulative incidence of HCC was 0.6% (0.4%-0.8%). This classification achieved a negative predictive value of 99.5% (99.4%-99.7%) to exclude patients without HCC development at 5 years. The AUROCs for the prediction of HCC with PAGE-B and mPAGE-B scores were similar at baseline and after 2 years on treatment. CONCLUSIONS: PAGE-B and mPAGE-B scores can be applied to identify patients on antiviral therapy who are at low risk of developing HCC. These patients could be exempted from HCC surveillance due to their very low HCC risk. LAY SUMMARY: Risk scores have been developed to predict the likelihood of patients with chronic hepatitis B developing hepatocellular carcinoma (HCC). We investigated the role of 2 such scores, PAGE-B and modified PAGE-B, in predicting the risk of HCC in 32,150 nucleos(t)ide analogue-treated patients with chronic hepatitis B. These scores identified a group of patients at very low risk of developing HCC who could therefore be exempted from HCC surveillance.
引用
- Yip TC, Wong GL, Wong VW, et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol. 2019. PMID: 31857194. doi:10.1016/j.jhep.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。